ASSOCIATION OF GENDER WITH STENT THROMBOSIS AND SHORT- TERM MAJOR ADVERSE CARDIOVASCULAR EVENTS IN PATIENTS UNDERGOING PRIMARY PERCUTANEOUS CORONARY INTERVENTION

被引:0
|
作者
Kumar, Aneel [1 ]
Kumar, Rajesh [2 ,4 ]
Mujtaba, Mustajab [2 ]
Ahmed, Rameez [2 ]
Rahooja, Kubbra [2 ]
Rasool, Ghulam [2 ]
Talpur, Mir Fahad Hussain [2 ]
Ali, Ahsan [2 ]
Basit, Abdul [2 ]
Samad, Maryam [2 ]
Yaqoob, Salma [2 ]
Siddiqui, Maria Noor [1 ]
Wadhwani, Anesh [3 ]
Kumar, Yogesh [3 ]
Raja, Rahul [3 ]
机构
[1] SMBZAN Inst Cardiol, Quetta, Pakistan
[2] Natl Inst Cardiovasc Dis, Karachi, Pakistan
[3] Dow Univ Hlth Sci, Karachi, Pakistan
[4] Natl Inst Cardiovasc Dis NICVD, Cardiol, Karachi, Pakistan
来源
PAKISTAN HEART JOURNAL | 2022年 / 55卷 / 03期
关键词
STEMI; primary PCI; stent thrombosis; MACE; gender; ELEVATION MYOCARDIAL-INFARCTION; DRUG-ELUTING STENTS; PREDICTORS; OUTCOMES; REVASCULARIZATION; MANAGEMENT; WOMEN; MEN;
D O I
10.47144/phj.v55i3.2306
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objectives: Gender has been reported to be an independent predictor of stent thrombosis (ST), however, very limited data are available regarding gender disparities in the incidence of ST after primary percutaneous coronary intervention (PCI). Therefore, the objective of this study was to compare the incidence of ST among males and females after primary PCI.Methodology: In this study, we included consecutive patients diagnosed with ST-elevation myocardial infarction undergoing primary PCI. The incidence of ST and short-term major adverse cardiovascular events (MACE) were compared between male and female cohorts.Results: The gender distribution was 21% (368) female and 79% (1388) male patients. In the unmatched cohorts of females and males, the incidence of ST was 3.3% (12) vs. 5.3% (74); p=0.102, respectively. Short-term all-cause mortality rate was 12.2% (45) vs. 8.6% (119); p=0.032 among female and male patients, respectively. After propensity matching of the baseline characteristics, the incidence of stent thrombosis was 3.3% (12) vs. 4.9% (18); p=0.263 among females and male counterparts, respectively. The short-term all-cause mortality rate was 12.2% (45) vs. 10.6% (39); p=0.487 among female and propensity-matched male cohorts, respectively. Conclusion: There are no gender-based disparities in the incidence of ST as well as short-term MACE after primary PCI. The gender of the patient itself does not determine the prognosis of the patient, but longer ischemic time, older age, and consequently higher burden of risk factors confound the effect of the female gender.
引用
收藏
页码:218 / 223
页数:6
相关论文
共 50 条
  • [31] COLCHICINE REDUCES MAJOR ADVERSE CARDIOVASCULAR EVENTS IN PATIENTS UNDERGOING PERCUTANEOUS CORONARY INTERVENTION: A META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS
    Fadhil, Ameer
    Al Wssawi, Abbas
    Gumera, Armand
    Hashim, Hashim Talib
    Al-Shammari, Ali Saad
    Abdeltawwab, Mohannad
    Amin, Mahmoud
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2024, 83 (13) : 919 - 919
  • [32] Short and long-term major adverse cardiac events in patients undergoing percutaneous coronary intervention with stenting for acute myocardial infarction complicated by cardiogenic shock
    Marcolino, Milena S.
    Simsek, Cihan
    de Boer, Sanneke P.
    van Domburg, Ron T.
    van Geuns, Robert-Jan
    de Jaegere, Peter
    Akkerhuis, K. Martijn
    Daemen, Joost
    Serruys, Patrick W.
    Boersma, Eric
    CIRCULATION, 2012, 125 (19) : E698 - E698
  • [33] Serum Corin Levels Predict Long Term Major Adverse Cardiovascular Events Post Percutaneous Coronary Intervention
    Peleg, Aviva
    Ghanim, Diab
    Naoum, Farid
    Suleman, Ahmad
    Qarawani, Dahud
    Hasin, Yonathan
    CIRCULATION, 2008, 118 (18) : S1084 - S1084
  • [34] SHORT- AND LONG-TERM CLINICAL OUTCOMES IN PATIENTS UNDERGOING RESCUE PERCUTANEOUS CORONARY INTERVENTION COMPARED WITH PRIMARY PERCUTANEOUS CORONARY INTERVENTION IN ST-ELEVATION MYOCARDIAL INFARCTION
    Chan, William
    Clark, David J.
    Ajani, Andrew E.
    Andrianopoulos, Nick
    Brennan, Angela L.
    Reid, Christopher M.
    Yip, Thomas
    Shaw, James A.
    Dart, Anthony M.
    Duffy, Stephen J.
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2010, 55 (10)
  • [35] Impaired thrombolytic status predicts adverse cardiac events in patients undergoing primary percutaneous coronary intervention
    Christopoulos, Christos
    Farag, Mohamed
    Sullivan, Keith
    Wellsted, David
    Gorog, Diana A.
    THROMBOSIS AND HAEMOSTASIS, 2017, 117 (03) : 457 - 470
  • [36] The Toronto risk score for major adverse cardiovascular events following percutaneous coronary intervention
    Ivanov, Joan
    Chowdhary, Saqib
    Horlick, Eric
    Seidelin, Peter
    Mackie, Karen
    Dzavik, Vlad
    CIRCULATION, 2006, 114 (18) : 842 - 842
  • [37] Short- and Long-term Outcomes in Patients with Connective Tissue Diseases Undergoing Percutaneous Coronary Intervention
    Zhou Li
    Chen Hui
    Li Wei-Ping
    Gao Hong-Li
    Li Dong-Bao
    Zhao Hui-Qiang
    Yao Dao-Kuo
    Li Hong-Wei
    中华医学杂志英文版, 2016, 129 (07) : 804 - 808
  • [38] Short- and Long-term Outcomes in Patients with Connective Tissue Diseases Undergoing Percutaneous Coronary Intervention
    Zhou, Li
    Chen, Hui
    Li, Wei-Ping
    Gao, Hong-Li
    Li, Dong-Bao
    Zhao, Hui-Qiang
    Yao, Dao-Kuo
    Li, Hong-Wei
    CHINESE MEDICAL JOURNAL, 2016, 129 (07) : 804 - 808
  • [39] Stent Thrombosis After Primary Percutaneous Coronary Intervention in Real World Patients
    Gomez, I
    Jimenez, V
    Baz, J. A.
    Bastos, G.
    de Miguel, A.
    Ortiz, A.
    Iniguez, A.
    CORONARY ARTERY DISEASE: 2011 UPDATE: FROM PREVENTION TO INTERVENTION, 2011, : 423 - 425
  • [40] Effect of CYP2C19 genetic variants on bleeding and major adverse cardiovascular events in a cohort of Arab patients undergoing percutaneous coronary intervention and stent implantation
    Ali, Zainab Omer
    Bader, Loulia
    Mohammed, Shaaban
    Arafa, Salaheddin
    Arabi, Abdulrahman
    Cavallari, Larisa
    Langaee, Taimour
    Mraiche, Fatima
    Rizk, Nasser
    Awaisu, Ahmed
    Shahin, Mohamed H.
    Elewa, Hazem
    PHARMACOGENETICS AND GENOMICS, 2022, 32 (05): : 183 - 191